Climb Bio Reports 3Q 2026 EPS Loss of $0.18
Climb Bio reported a higher net loss than a year earlier, as increased research and development costs were partly offset by higher interest income.
Climb Bio reported a higher net loss in 3Q 2026 than a year earlier. Higher research and development costs, mainly from advancing CLYM116 and budoprutug, were partly offset by increased interest income from higher average invested balances.Financial Highlights² Reported as “Net loss”. ³ Reported as…